X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (294) 294
index medicus (218) 218
male (214) 214
oncology (208) 208
middle aged (160) 160
aged (155) 155
female (148) 148
adult (108) 108
cancer (97) 97
aged, 80 and over (77) 77
treatment outcome (76) 76
research (70) 70
kidney neoplasms - drug therapy (64) 64
carcinoma, renal cell - drug therapy (61) 61
animals (60) 60
article (58) 58
antineoplastic agents - therapeutic use (55) 55
urology & nephrology (55) 55
survival (48) 48
chemotherapy (47) 47
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
kidney neoplasms - pathology (44) 44
care and treatment (43) 43
analysis (41) 41
carcinoma (41) 41
disease-free survival (39) 39
neoplasm metastasis (38) 38
prostate cancer (37) 37
expression (36) 36
therapy (34) 34
phylogeny (33) 33
prostatic neoplasms - drug therapy (32) 32
survival analysis (32) 32
clinical trials (31) 31
metastasis (31) 31
carcinoma, renal cell (29) 29
drug therapy (28) 28
prognosis (28) 28
antineoplastic agents - adverse effects (27) 27
mice (27) 27
research article (27) 27
drug administration schedule (26) 26
health aspects (26) 26
bevacizumab (25) 25
endothelial growth-factor (25) 25
medicine & public health (25) 25
abridged index medicus (24) 24
carcinoma, renal cell - mortality (24) 24
carcinoma, renal cell - pathology (24) 24
deoxycytidine - analogs & derivatives (24) 24
pharmacology & pharmacy (24) 24
disease progression (23) 23
time factors (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
gemcitabine (22) 22
gene expression (22) 22
genes (22) 22
kidney neoplasms - mortality (22) 22
neoplasm staging (22) 22
prostatic neoplasms - pathology (22) 22
survival rate (22) 22
angiogenesis (21) 21
carcinoma, renal cell - secondary (21) 21
proteins (21) 21
renal cell carcinoma (21) 21
deoxycytidine - administration & dosage (20) 20
immunotherapy (20) 20
life sciences (20) 20
usage (20) 20
apoptosis (19) 19
clinical-trials (19) 19
evolution (19) 19
mycology (19) 19
prospective studies (19) 19
risk factors (19) 19
tumors (19) 19
cell biology (18) 18
combination (18) 18
growth (18) 18
hematology, oncology and palliative medicine (18) 18
infusions, intravenous (18) 18
medicine (18) 18
niacinamide - analogs & derivatives (18) 18
solid tumors (18) 18
trial (18) 18
urinary bladder neoplasms - drug therapy (18) 18
urology (18) 18
biochemistry & molecular biology (17) 17
doxorubicin (17) 17
genetic aspects (17) 17
identification (17) 17
physiological aspects (17) 17
prostate-specific antigen - blood (17) 17
urinary bladder neoplasms - pathology (17) 17
biology (16) 16
bladder cancer (16) 16
cells (16) 16
interferon-alpha (16) 16
microbiology (16) 16
radiology, nuclear medicine & medical imaging (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 12, pp. 1402 - 1418
Journal Article
JOURNAL OF ONCOLOGY PRACTICE, ISSN 1554-7477, 08/2019, Volume 15, Issue 8, pp. 429 - 429
Journal Article
Nucleic Acids Research, ISSN 0305-1048, 01/2017, Volume 45, Issue 1, pp. D128 - D134
RNAcentral is a database of non-coding RNA (ncRNA) sequences that aggregates data from specialised ncRNA resources and provides a single entry point for... 
GENE | GENOME DATABASE | LANDSCAPE | SEARCH | BIOCHEMISTRY & MOLECULAR BIOLOGY | TARGETS | MICRORNAS | EXPRESSION | RESOURCE | REVEALS | Animals | Sequence Analysis, RNA | Species Specificity | Genomics | Humans | RNA, Untranslated - chemistry | Databases, Nucleic Acid | Nucleotides - chemistry | genome | rna | BASIC BIOLOGICAL SCIENCES | nucleotides | Database Issue
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 13, pp. 1534 - 1540
Journal Article
Science, ISSN 0036-8075, 3/2014, Volume 343, Issue 6176, pp. 1221 - 1228
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma
Journal Article